API | amibegron

amibegron Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Amibegron (SR-58,611A) was a drug developed by Sanofi-Aventis which acts as a selective agonist for the β3 adrenergic receptor. It is the first orally active β3 agonist developed that is capable of entering the central nervous system, and has antidepressant and anxiolytic effects. ^Wikipedia

Chemistry

SMILES: CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c3cccc(Cl)c3
InChIKey: RDJQCOBTKKAQAH-FPOVZHCZSA-N
Mol. Mass: 403.91
ALogP: 3.46 Partition coefficient
ChEMBL Molecules:

amibegron

amibegron hydrochloride

More Chemistry

Pharmacology

Mechanism of Action:
- Beta-3 adrenergic receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

acetic acid, ((7-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)-5,6,7,8-tetrahydro-2-naphthalenyl)oxy)-, ethyl ester, hydrochloride, (r-(r*,s*))- | amibegron | amibegron hcl | amibegron hydrochloride | sr 58611 | sr-58611 | sr58611a | sr 58611a | sr-58611a

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (2)

Anxiety

Depression

Experimental Indications - Clinical Trial Phases 1-4 (4)

Anxiety Disorders (Phase 3)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Depressive Disorder, Major (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 14
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue